A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor: 3D Medicines (Sichuan) Co., Ltd.
Listed as NCT03248843, this PHASE1 trial focuses on Advanced or Metastatic Solid Tumors and remains completed. Sponsored by 3D Medicines (Sichuan) Co., Ltd., it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2021 — Mar 2022 [monthly]
Unknown Status PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE1
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2020 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- 3D Medicines (Sichuan) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .